[Chronic actinic dermatitis: treatment with topical tacrolimus (two cases)]

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Chronic actinic dermatitis (CAD) typically requires systemic immunosuppressive therapy.
• Treatment resistance and drug intolerance are common challenges in managing CAD.

Observation:

• Two male patients with CAD, previously treated with systemic immunosuppressants, were switched to topical tacrolimus.
• Dramatic improvement in cutaneous lesions was observed within two months of topical tacrolimus application.
• Lesion recurrence occurred immediately upon cessation of daily topical tacrolimus treatment.

Findings:

• Topical tacrolimus demonstrates significant efficacy in treating chronic actinic dermatitis, as supported by these cases and existing literature.
• Tacrolimus, by targeting T lymphocytes, offers a logical therapeutic approach for CAD.
• Rapid symptom recurrence upon dose reduction suggests the need for prolonged, potentially lifelong, topical tacrolimus treatment.

Implications:

• Topical tacrolimus presents a viable alternative for CAD patients intolerant to or resistant to systemic therapies.
• Long-term safety data (up to three years) is available, but theoretical concerns regarding carcinogenicity warrant extended patient follow-up.
• The findings highlight the critical need for sustained treatment and vigilant monitoring in managing chronic actinic dermatitis with topical tacrolimus.